PEPG vs WVE
PEPG: PepGen is a clinical-stage biotechnology company developing peptide-enhanced oligonucleotide therapies to treat severe neuromuscular diseases, with a primary focus on Myotonic Dystrophy Type 1. WVE: Wave Life Sciences is a clinical-stage biotech company developing stereopure nucleic acid therapeutics via its proprietary PRISM platform to treat genetically defined diseases.
Side-by-side fundamentals
| Metric | PEPG | WVE | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $2.72 | $3.37 | |
| Market cap | $188M | $664M | |
| Net margin FY2025, SEC XBRL | n/a | -478.3% | |
| Operating margin FY2025, SEC XBRL | n/a | -504.1% | |
| ROE FY2025, SEC XBRL | -60.8% | -39.4% | WVE higher |
| ROA FY2025, SEC XBRL | -51.6% | -32.0% | WVE higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | -60.5% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +127.1% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.50 | 1.46 | |
| 1-year return as of 2026-10-21 close | -44.3% | -57.1% | PEPG higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.